Inside retatrutide’s black market, Eli Lilly’s 6 new lawsuits, and a brewing FDA battle
Industry Buzz
All the retatrutide that’s out right now is not through an FDA manufacturer. … For me, it comes down to safety, and we can’t confirm the purity or any of the safety with any of the versions of retatrutide that are out there right now.
—Spencer Nadolsky, DO
Eli Lilly is taking an increasingly aggressive approach to a drug it does not yet have FDA approval to sell.
The company recently filed six lawsuits against businesses it alleges are illegally marketing and selling versions of retatrutide, its investigational obesity drug.[][]
The targets include online peptide sellers, medical spas, and other companies accused of offering products labeled as retatrutide despite the drug remaining in phase 3 development and unapproved for human use.[]
Related: One high-profile patient’s access to Eli Lilly’s experimental obesity drug has sparked a much larger debateOn its face, the argument is relatively straightforward: Patients buying an unapproved peptide online may have little idea what is actually in the vial, how it was manufactured, or whether its potency and sterility are reliable.
The FDA has also said that unapproved versions of retatrutide cannot legally be compounded and sold to consumers.[]
But Eli Lilly’s campaign against the emerging retatrutide market intersects with another, quieter legal battle that could have much bigger implications for the drug’s future: Which category will the FDA regulate retatrutide under—as a drug, or as a biologic?
Why Eli Lilly wants retatrutide treated as a biologic
Eli Lilly has challenged the FDA’s classification of retatrutide and wants it regulated as a biological product, which would generally mean pursuing licensure through a Biologics License Application rather than the conventional drug approval pathway.[]
Eli Lilly sued the FDA after the agency concluded that retatrutide did not meet its criteria for classification as a biological product.[]The dispute turns in part on how the FDA counts amino acids when determining whether a peptide qualifies as a protein—and whether retatrutide could alternatively be considered sufficiently analogous to a protein to fall within the biologics framework.
In September 2025, a federal court set aside the FDA’s interpretation of the “analogous” category and sent the matter back to the agency for further consideration. The court did not, however, simply declare retatrutide a biologic. The classification question remains consequential, and Eli Lilly continued to challenge it in 2026.[]
Eli Lilly has argued that the classification has important consequences for development, marketing exclusivity, and compounding eligibility.
And that last point may be particularly important as Eli Lilly prepares to bring what could become another blockbuster obesity medicine to market.
The compounding question is where the lawsuits and biologic fight converge
Retatrutide is already attracting enormous attention because of its potential efficacy. The drug acts on three hormone pathways—GLP-1, GIP, and glucagon—and recent phase 3 results have reinforced expectations that it could become a major player in obesity treatment if approved.[] Eli Lilly is preparing regulatory submissions, with reports indicating it may seek US authorization in early 2027.[]
“The trials look amazing. We’re going to hit probably around bariatric surgery–level amounts of weight loss, including other metabolic markers that improve beyond just the weight loss, like LDL cholesterol reduction,” said Spencer Nadolsky, DO, a board-certified family medicine physician, in an Instagram Reel.
The result is a regulatory gap physicians should know about: Compounded and gray-market retatrutide is reaching patients before any FDA-approved formulation exists.[]
That is the backdrop for the six new lawsuits. Eli Lilly alleges that companies are exploiting demand for an experimental drug by selling products that have not undergone FDA review for safety, effectiveness, or manufacturing quality.[]
From a patient-safety perspective, that concern is difficult to dismiss. The risks associated with patients obtaining injectable products from unregulated or questionable sources are real, particularly when the actual identity, concentration, purity, and sterility of the product cannot be independently verified.
“All the retatrutide that’s out right now is not through an FDA manufacturer. None of it is FDA-approved. For me, it comes down to safety, and we can’t confirm the purity or any of the safety with any of the versions of retatrutide that are out there right now. They’re coming through sketchy sources, and I just would never recommend [it] to a family member, or myself for that matter,” Dr. Nadolsky said.
At the same time, Eli Lilly’s push for biologic classification could potentially give it a stronger long-term position against would-be follow-on or compounded versions.
For physicians, that distinction is worth keeping in mind as the public debate increasingly frames every dispute over obesity-drug compounding as either entirely about patient safety or entirely about pharmaceutical profits. The reality is more complicated.
Related: Your clinical guide: Managing patients using 'peptide stacks' for chronic pain and anti-agingDoes biologic status automatically mean higher prices? Not necessarily
Insulins transitioned to a regulatory framework for biologics in the US in March 2020 under the Biologics Price Competition and Innovation Act.[] But it would be inaccurate to say that insulin prices suddenly skyrocketed because the FDA labeled insulin a biologic.
In fact, US insulin pricing had been a major problem long before the 2020 transition. List prices had already risen dramatically over preceding years, driven by a complicated mix of factors including patent and product strategies, limited competition, rebates, pharmacy benefit manager negotiations, and the structure of the insulin market.[]
The biologics framework may affect how competition eventually develops because biologics and biosimilars follow a different regulatory pathway than traditional small-molecule drugs and generics.[] There is currently no basis to say that retatrutide will be more expensive because Eli Lilly is pursuing biologic status. The drug has not yet been approved, and Eli Lilly has not established its eventual list price.
Still, the broader concern is understandable. If biologic classification produces stronger barriers to certain forms of competition or longer periods before lower-cost alternatives can enter the market, that could affect the competitive environment surrounding retatrutide over time.
What doctors should watch
For clinicians, the immediate issue may be less about the legal theory and more about what patients are likely to read online.
Retatrutide already has the kind of hype that can make an investigational drug seem commercially available long before it actually is. Patients may encounter websites, med spas, social media posts, and peptide vendors using familiar language around “research peptides” or purported versions of the drug.
Related: How to talk to patients about psychedelic therapy amid media buzzThe clearest clinical message is that retatrutide is not currently FDA-approved for patient use. Products sold outside legitimate clinical trials have not been reviewed by the FDA as approved retatrutide therapies, regardless of how they are marketed.
The bigger story, though, may be what happens after approval. Eli Lilly’s lawsuits against alleged sellers of black-market retatrutide and its separate fight over biologic classification could ultimately converge around the same question: How much control will the manufacturer have over the market for a drug expected to generate extraordinary demand?
Eli Lilly can reasonably argue that tighter control helps protect patients from unapproved and potentially dangerous copycat products. Critics can reasonably ask whether the same regulatory structure could also make it harder for lower-cost competition to emerge.
For now, both questions remain open. And as retatrutide moves closer to the market, physicians may find themselves once again at the center of a familiar tension in American medicine: The need to protect patients from unsafe products while also ensuring that a breakthrough therapy does not become inaccessible to the patients who need it most.